With more-advanced renal failure, phosphate binders become necessary to maintain phosphate balance and to prevent hyperphosphatemia. Because of toxicity, aluminum-containing phosphate binders are ...

Nonadherence to phosphate binders is a significant challenge ... the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). OLC has over forty issued and granted patents ...

rather than aluminium-containing oral phosphate binders. Limited evidence suggests that aluminium bone disease may also be on the decline in the era of aluminium removal from dialysis fluid ...

A change in Medicare coverage for some dialysis medications has left nursing homes and their patients receiving in-house treatment for kidney failure in a serious bind.

(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the ... on the limitations of current phosphate binders and their effect on patients ...

Nonadherence to phosphate binders is a significant challenge contributing ... that occurs in nearly all patients with End Stage Renal Disease (ESRD). If left untreated, hyperphosphatemia leads ...

Nonadherence to phosphate binders is a significant challenge ... the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). OLC has over forty issued and granted patents ...

Nonadherence to phosphate binders is a significant challenge contributing to elevated phosphate levels ... Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End ...